Revenue + Forward P/E
Vertex Pharmaceuticals Incorporated (VRTX) quarterly revenue and forward P/EForward P/E: 27.0x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$133.26B
Enterprise value
$117.65B
P/E ratio (TTM)
28.06x
P/S ratio (TTM)
9.89x
P/B ratio
6.26x
EV/Sales
9.60x
EV/EBITDA
21.82x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$12.07B
Gross profit (TTM)
$10.27B
Operating income (TTM)
$4.76B
EBITDA (TTM)
$4.86B
Net income (TTM)
$3.95B
Free cash flow (TTM)
$3.19B
Margins & returns
Gross margin
86.28%
Operating margin
38.97%
Profit margin
35.40%
Return on equity
23.93%
Return on assets
16.38%
Per-share metrics
EPS (TTM)
$17.07
Dividend yield
0.00%
Beta
0.29
Capital structure
Cash & equivalents
$5.09B
Total debt
$3.88B
Net debt
$-1.21B
Shares outstanding
253.81M
Financial health
Current ratio
2.90
Debt / equity
0.21
Debt / assets
0.15
Interest coverage
357.95
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.91B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.10B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.06B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.91B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $133.26B | 28.06x | 9.89x | 21.82x | - |